Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)

ClinicalTrials.gov ID: NCT01185301

Public ClinicalTrials.gov record NCT01185301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 12:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy With Adalimumab in Subjects With Early Rheumatoid Arthritis (CONCERTO)

Study identification

NCT ID
NCT01185301
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Enrollment
395 participants

Conditions and interventions

Interventions

  • adalimumab Biological
  • methotrexate Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2010
Primary completion
Aug 31, 2012
Completion
Aug 31, 2012
Last update posted
Nov 14, 2013

2010 – 2012

United States locations

U.S. sites
30
U.S. states
20
U.S. cities
29
Facility City State ZIP Site status
Site Reference ID/Investigator# 38973 Huntsville Alabama 35801
Site Reference ID/Investigator# 41962 Mesa Arizona 85202
Site Reference ID/Investigator# 39260 Phoenix Arizona 85031
Site Reference ID/Investigator# 45323 Little Rock Arkansas 72205
Site Reference ID/Investigator# 38912 Hemet California 92543
Site Reference ID/Investigator# 39673 Victorville California 92395
Site Reference ID/Investigator# 38909 Jacksonville Florida 32209
Site Reference ID/Investigator# 40422 Miami Florida 33169
Site Reference ID/Investigator# 38910 Sarasota Florida 34239
Site Reference ID/Investigator# 44284 Atlanta Georgia 30312
Site Reference ID/Investigator# 38907 Gainesville Georgia 30501
Site Reference ID/Investigator# 38972 Lawrenceville Georgia 30045
Site Reference ID/Investigator# 39670 Rock Island Illinois 61201
Site Reference ID/Investigator# 42282 Springfield Illinois 62704
Site Reference ID/Investigator# 38911 Wichita Kansas 67203
Site Reference ID/Investigator# 39672 Covington Louisiana 70433
Site Reference ID/Investigator# 42204 Omaha Nebraska 68114
Site Reference ID/Investigator# 40651 Clifton New Jersey 07012
Site Reference ID/Investigator# 41422 Freehold New Jersey 07728
Site Reference ID/Investigator# 41424 The Bronx New York 10467
Site Reference ID/Investigator# 40463 Greenville North Carolina 27834
Site Reference ID/Investigator# 42202 Columbus Ohio 43213
Site Reference ID/Investigator# 44282 Norman Oklahoma 73069
Site Reference ID/Investigator# 41423 Duncansville Pennsylvania 16635
Site Reference ID/Investigator# 38971 Charleston South Carolina 29406
Site Reference ID/Investigator# 39666 Jackson Tennessee 38305
Site Reference ID/Investigator# 39643 Dallas Texas 75231
Site Reference ID/Investigator# 45325 Dallas Texas 75246
Site Reference ID/Investigator# 52042 Houston Texas 77074
Site Reference ID/Investigator# 40602 Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01185301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 14, 2013 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01185301 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →